 |
2019 News Releases
December 16, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
December 13, 2019 -
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS
Read
December 12, 2019 - plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer
Read
December 11, 2019 - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
Read
December 2, 2019 - Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
Read
December 2, 2019 - Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries
Read
November 6, 2019 - Puma Biotechnology Reports Third Quarter 2019 Financial Results
Read
November 5, 2019 - Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
Read
November 4, 2019 - Puma Biotechnology to Present at the Credit Suisse Healthcare Conference
Read
October 23, 2019 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read
October 3, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
October 2, 2019 - FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
September 25, 2019 - Puma Biotechnology to Present at Cantor Global Healthcare Conference
Read
September 11, 2019 - Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read
September 5, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
September 4, 2019 - Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer
Read
September 3, 2019 - FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases
Read
September 3, 2019 - Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Read
August 8, 2019 - Puma Biotechnology Reports Second Quarter 2019 Financial Results
Read
August 6, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
July 25, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
July 24, 2019 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read
July 16, 2019 - Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer
Read
July 3, 2019 - Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019
Read
July 1, 2019 - Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read
June 5, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
June 4, 2019 - Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2 Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting
Read
June 2, 2019 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
Read
May 29, 2019 - Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference
Read
May 9, 2019 - Puma Biotechnology Reports First Quarter 2019 Financial Results
Read
May 8, 2019 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019
Read
April 25, 2019 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read
April 9, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
April 4, 2019 - Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations
Read
April 1, 2019 - Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe
Read
March 28, 2019 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019
Read
March 18, 2019 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting - Oral Plenary Presentation Receives SGO Presidential Award
Read
March 18, 2019 - Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
March 5, 2019 - Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
Read
February 28, 2019 - Puma Biotechnology Reports Fourth Quarter and Full Year
2018 Financial Results
Read
February 15, 2019 - Puma Biotechnology Reports Inducement Awards Under
Nasdaq Listing Rule 5635(c)(4)
Read
February 13, 2019 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Read
February 4, 2019 - Puma Biotechnology Announces Litigation Victory with Jury’s Decision
Read
January 11, 2019 - Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada
Read
January 3, 2019 - Puma Biotechnology to Present at J. P. Morgan Healthcare Conference
Read
January 2, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
2018 News Releases
December 17, 2018 - Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer
Read
December 11, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read
December 10, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read
December 6, 2018 - Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read
December 6, 2018 - Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read
December 6, 2018 - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read
December 3, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
November 7, 2018 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read
November 1, 2018 - Puma Biotechnology Reports Third Quarter 2018 Financial Results
Read
October 18, 2018 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read
October 10, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
October 2, 2018 - Puma Biotechnology's Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX® (neratinib) in China
Read
September 20, 2018 - Puma Biotechnology to Present at Cantor Global Healthcare Conference
Read
September 6, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
September 4, 2018 - European Commission Grants Marketing Authorisation for Puma Biotechnology's NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer
Read
August 9, 2018 - Puma Biotechnology Reports Second Quarter 2018 Financial Results
Read
July 31, 2018 - Puma Biotechnology Files New Drug Submission for NERLYNX® in Canada
Read
July 26, 2018 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read
July 17, 2018 - Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial)
Read
June 29, 2018 - Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX® for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
June 26, 2018 - Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
June 2, 2018 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting
Read
May 30, 2018 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference
Read
May 9, 2018 - Puma Biotechnology Reports First Quarter 2018 Financial Results
Read
May 8, 2018 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018
Read
April 25, 2018 - Puma Biotechnology to Host Conference Call to Discuss
First Quarter Financial Results
Read
April 3, 2018 - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Read
April 2, 2018 - NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination with Capecitabine or Paclitaxel as Treatment Options for Patients with Breast Cancer Brain Metastases
Read
March 6, 2018 - Puma Biotechnology to Present at Cowen's Annual Healthcare Conference
Read
March 1, 2018 - Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results
Read
February 23, 2018 - Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
February 15, 2018 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Read
February 7, 2018 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference
Read
February 1, 2018 - Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China
Read
January 31, 2018 - Puma Biotechnology Announces Publication of Results from Phase II SUMMIT 'Basket' Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers - Data published online today in Nature -
Read
January 30, 2018 - Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel
Read
January 29, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read
January 23, 2018 - Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
2017 News Releases
December 14, 2017 - Puma Biotechnology Added to NASDAQ Biotechnology Index
Read
December 13, 2017 - Puma Biotechnology Announces Meeting of Scientific Advisory Group on Oncology in Europe to Review Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
December 12, 2017 - Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
Read
December 11, 2017 - Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings
Patent Claims for Extended Adjuvant Treatment Upheld
Read
December 6, 2017 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
Read
November 22, 2017 - Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia
Read
November 13, 2017 - Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology
Data Demonstrates Continued Benefit from Neratinib after 5 years in Extended Adjuvant HER2-Positive Breast Cancer
Read
November 9, 2017 - Puma Biotechnology Reports Third Quarter 2017 Financial Results
Results include the initial sales of NERLYNX® in the U.S.
Read
November 8, 2017 - Puma Biotechnology to Present at Stifel Healthcare Conference
Read
November 2, 2017 - Puma Biotechnology Secures $100 Million Term Loan from Silicon Valley Bank and Oxford Finance
Read
October 31, 2017 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read
October 26, 2017 - Puma Biotechnology to Host Conference Call to Discuss
Third Quarter Financial Results
Read
September 18, 2017 - Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference
Read
September 8, 2017 - Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress
Data Demonstrates Continued Benefit from Neratinib after 5 years
Read
August 31, 2017 - Puma Biotechnology to Participate in Panel Discussion at
Citi’s Biotech Conference
Read
August 30, 2017 - Puma Biotechnology Announces Publication of Abstracts for ESMO 2017
Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer
Read
August 25, 2017 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing
Rule 5635(c)(4)
Read
August 9, 2017 - Puma Biotechnology Reports Second Quarter 2017 Financial Results
Read
August 2, 2017 - Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP)
Read
July 31, 2017 - Puma Announces Availability of NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in the United States
Read
July 17, 2017 - U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
July 6, 2017 - Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial
Read
June 3, 2017 - Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting
Read
May 31, 2017 - Puma Biotechnology to Present at the Jefferies 2017 Healthcare Conference
Read
May 24, 2017 - Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib
Read
May 22, 2017 - Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting
Read
May 17, 2017 - Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting
Read
May 10, 2017 - Puma Biotechnology Reports First Quarter 2017 Financial Results
Read
May 9, 2017 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2017 Health Care Conference
Read
April 17, 2017 - Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
April 4, 2017 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage
Breast Cancer at the 2017 AACR Annual Meeting
Read
April 2, 2017 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting
Read
April 2, 2017 - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting
Read
April 2, 2017 - Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers
Caligor Opco LLC to Provide Regulatory and Logistical Management
Read
March 2, 2017 - Puma Biotechnology to Present at Cowen’s Health Care Conference
Read
March 1, 2017 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017
Read
March 1, 2017 - Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272
Read
March 1, 2017 - Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results
Read
February 14, 2017 - Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference
Read
February 8, 2017 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference
Read
January 6, 2017 - Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients
Read
January 3, 2017 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference
Read
2016 News Releases
December 19, 2016 - Puma Biotechnology to Move Stock Exchange Listing to Nasdaq
Ticker symbol to remain PBYI
Read
December 8, 2016 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
Read
December 7, 2016 - Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
Read
December 7, 2016 - Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
Read
December 6, 2016 - Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States
Caligor Opco LLC to provide regulatory, logistical and supply chain support
Read
November 14, 2016 - Puma Biotechnology Announces Presentations of Investigational Data at the
San Antonio Breast Cancer Symposium (SABCS)
Read
November 9, 2016 - Puma Biotechnology Reports Third Quarter 2016 Financial Results
Read
October 31, 2016 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read
October 25, 2016 - Puma Biotechnology Closes $172 Million Public Offering of Common Stock
Read
October 21, 2016 - Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Share
Read
October 19, 2016 - Puma Biotechnology Prices Public Offering of Common Stock
Read
October 18, 2016 - Puma Biotechnology Announces Proposed Public Offering of Common Stock
Read
September 20, 2016 - Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
August 22, 2016 - Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
Read
August 9, 2016 - Puma Biotechnology Reports Second Quarter 2016 Financial Results
Read
July 21, 2016 - Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
Read
July 21, 2016 - Puma Biotechnology Submits New Drug Application for PB272 (Neratinib)
to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
July 7, 2016 - Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine
Read
June 27, 2016 - Puma Biotechnology Submits Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
Read
June 5, 2016 - Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting
Read
May 18, 2016 - Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting
Read
May 17, 2016 - Puma Biotechnology to Present at UBS Global Healthcare Conference
Read
May 10, 2016 - Puma Biotechnology Reports First Quarter 2016 Financial Results
Read
May 4, 2016 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference
Read
Apr. 20, 2016 - Puma Biotechnology’s Neratinib Featured in Poster Presentations
at the AACR Annual Meeting 2016
Read
Apr. 14, 2016 - Puma Biotechnology’s NEfERT-T Phase II Study Published Online in JAMA Oncology
Read
Mar. 28, 2016 - Puma Biotechnology Updates Timeline for Filing New Drug Application NDA Filing Currently Anticipated Mid-2016
Read
Mar. 18, 2016 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016
Read
Mar. 2, 2016 - Puma Biotechnology to Present at Cowen’s Health Care Conference
Read
Feb. 29, 2016 - Puma Biotechnology Reports Fourth Quarter and Full Year 2015 Financial Results
Read
Feb. 17, 2016 - Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference
Read
Feb. 16, 2016 - Puma Biotechnology Announces the Conclusion and Final Results of Eshelman’s Consent Solicitation
Read
Feb. 11, 2016 - Puma Biotechnology’s ExteNET Phase III Study Published Online in The Lancet Oncology
Read
Feb. 3, 2016 - Puma Biotechnology to Participate in Fireside Chat at Leerink Partners Global Healthcare Conference
Read
Jan. 8, 2016 - Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman’s Consent Solicitation
Read
Jan. 4, 2016 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference
Read
2015 News Releases
Dec. 30, 2015 - Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card
Read
Dec. 29, 2015 - Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card
Read
Dec. 23, 2015 - ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card
Read
Dec. 18, 2015 - Puma Biotechnology Expands Third Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
Read
Dec. 16, 2015 - Puma Biotechnology to Host Conference Call to Discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea
Read
Dec. 11, 2015 - Puma Biotechnology Presents 3-Year Disease Free Survival Data from Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) at the 2015 San Antonio Breast Cancer Symposium
Read
Dec. 10, 2015 - Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2015 San Antonio Breast Cancer Symposium
Read
Dec. 10, 2015 - Puma Biotechnology Announces Results of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer
Read
Nov. 30, 2015 - Puma Biotechnology Provides Update from Meeting with European Medicines Agency
Read
Nov. 13, 2015 - Puma Biotechnology to Present Data at the San Antonio
Breast Cancer Symposium (SABCS)
Read
Nov. 9, 2015 - Puma Biotechnology Reports Third Quarter 2015 Financial Results
Read
Nov. 3, 2015 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read
Sept. 26, 2015 - Puma Biotechnology Announces Presentation of Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) in Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients
Read
Sept. 10, 2015 - Puma Biotechnology Announces Publication of PB272 in HER2 Non-Amplified Metastatic Breast Cancer with a HER2 mutation
Read
Aug. 10, 2015 - Puma Biotechnology Reports Second Quarter 2015 Financial Results
Read
June 4, 2015 - Puma Biotechnology to Present at Goldman Sachs Healthcare Conference
Read
June 1, 2015 - Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival
Read
May 27, 2015 - Puma Biotechnology to Present at Jefferies 2015 Healthcare Conference
Read
May 13, 2015 - Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
Read
May 12, 2015 - Puma Biotechnology to Participate in Fireside Chat at UBS Global Healthcare Conference
Read
May 11, 2015 - Puma Biotechnology Reports First Quarter 2015 Financial Results
Read
May 6, 2015 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference
Read
April 30, 2015 - Puma Biotechnology to Present at Deutsche Bank Health Care Conference
Read
April 14, 2015 - Puma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
Read
Mar. 10, 2015 - Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer
Read
Mar. 2, 2015 - Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results
Read
Feb. 24, 2015 - Puma Biotechnology to Present at Cowen Health Care Conference
Read
Feb. 18, 2015 - Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets’ Global Healthcare Conference
Read
Feb. 5, 2015 - Puma Biotechnology to Present at Leerink Global Healthcare Conference
Read
Jan. 27, 2015 - Puma Biotechnology Closes $218 Million Public Offering of Common Stock
Read
Jan. 22, 2015 - Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares
Read
Jan. 21, 2015 - Puma Biotechnology Prices Public Offering of Common Stock
Read
Jan. 20, 2015 - Puma Biotechnology Announces Proposed Public Offering
Read
Jan. 5, 2015 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference
Read
2014 News Releases
Dec. 12, 2014 - Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium
Interim Phase II Results Demonstrate Efficacy of PB272 in Combination with Temsirolimus
in HER2+ Metastatic Breast Cancer
Read
Dec. 2, 2014 - Puma Biotechnology Updates Timeline for Filing New Drug Application
-NDA Filing Currently Anticipated for Q1 2016
Read
Nov. 13, 2014 - Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive Metastatic Breast Cancer (NEfERTT Trial)
Read
Nov. 12, 2014 - Puma Biotechnology to Present at Stifel 2014 Healthcare Conference
Read
Nov. 10, 2014 - Puma Biotechnology Reports Third Quarter 2014 Financial Results
Read
Sept. 29, 2014 - Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer
Read
Sept. 3, 2014 - Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014
Read
Aug. 11, 2014 - Puma Biotechnology Reports Second Quarter 2014 Financial Results
Read
July 22, 2014 - Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 Trial in Adjuvant Breast Cancer (ExteNET Trial)
Read
July 22, 2014 - Puma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer
Read
June 5, 2014 - Puma Biotechnology to Present at the Goldman Sachs 35th Annual Global Healthcare Conference
Read
June 1, 2014 - Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data at the 2014 ASCO Annual Meeting
Read
May 29, 2014 - Puma Biotechnology to Present at Jefferies 2014 Global Healthcare Conference
Read
May 15, 2014 - Puma Biotechnology to Present at UBS Global Healthcare Conference
Read
May 14, 2014 - Puma Biotechnology Expands Cohort in Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients
Read
May 12, 2014 - Puma Biotechnology Reports First Quarter 2014 Financial Results
Read
May 7, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2014 Health Care Conference
Read
Apr. 7, 2014 - Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL
Read
Mar. 12, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch Smid Cap Conference
Read
Mar. 5, 2014 - Puma Biotechnology Announces Oral Presentation on I-SPY2 TRIAL at AACR Annual Meeting 2014
Read
Mar. 3, 2014 - Puma Biotechnology Reports Fourth Quarter and Full Year 2013 Financial Results
Read
Feb. 25, 2014 - Puma Biotechnology to Present at Cowen Health Care Conference
Read
Feb. 14, 2014 - Puma Biotechnology Closes $138 Million Public Offering of Common Stock
Read
Feb. 12, 2014 - Puma Biotechnology Announces Underwriters' Full Exercise of Option to Purchase Additional Shares
Read
Feb. 11, 2014 - Puma Biotechnology Prices Public Offering of Common Stock
Read
Feb. 6, 2014 - Puma Biotechnology Announces Positive Outcome
of European Opposition Proceedings
Read
2013 News Releases
Dec. 17, 2013 - Puma Biotechnology to Hold Conference Call to Provide Update on PB272 Clinical Trials in Patients with HER2 Mutations Read
Dec. 4, 2013 - Puma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL
Neratinib Graduates from I-SPY 2 TRIAL Read
Nov. 12, 2013 - Puma Biotechnology Reports Third Quarter 2013 Financial Results Read
Oct. 4, 2013 - Puma Biotechnology Initiates Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients Read
Sept. 4, 2013 - Puma Biotechnology to Present at Stifel Healthcare Conference Read
Aug. 6, 2013 - Puma Biotechnology Reports Second Quarter 2013 Financial Results Read
June 24, 2013 - Puma Biotechnology to Join Russell 3000 Index Read
June 7, 2013 - Puma Biotechnology Initiates Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Read
June 5, 2013 - Puma Biotechnology to Present at Goldman Sachs Healthcare Conference Read
May 29, 2013 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference Read
May 17, 2013 - Puma Biotechnology Comment on Trading Activity Read
May 14, 2013 - Puma Biotechnology to Present at UBS Global Healthcare Conference Read
May 9, 2013 - Puma Biotechnology Reports First Quarter 2013 Financial Results Read
May 8, 2013 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2013 Health Care Conference Read
April 1, 2013 - Puma Biotechnology Reports Fourth Quarter and Full Year 2012 Financial Results Read
Feb. 26, 2013 - Puma Biotechnology to Present at Cowen Health Care Conference Read
Feb. 20, 2013 - Puma Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Read
Feb. 6, 2013 - Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference Read
2012 News Releases
December 7, 2012 - Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Phase II Results Demonstrate Efficacy of PB272 in Combination with Temsirolimus in HER2+ Metastatic Breast Cancer
Read
Nov. 14, 2012 - Puma Biotechnology Reports Third Quarter 2012 Financial Results
Read
Nov. 7, 2012 - Puma Biotechnology to Present at Lazard Healthcare Conference
Read
October 24, 2012 - Puma Biotechnology Closes $138 Million Public Offering of Common Stock
Read
October 22, 2012 - Puma Biotechnology Announces Underwriters' Full Exercise of Overallotment Option, Increasing Total Offering Size to $138 Million
Read
October 18, 2012 - Puma Biotechnology Announces Upsizing and Pricing of $120 Million Public Offering of Common Stock
Read
September 12, 2012 - Puma Biotechnology to Present at UBS Global Life Sciences Conference
Read
August 29, 2012 - Puma Biotechnology to Present at Stifel Nicolaus 2012 Healthcare Conference
Read
August 14, 2012 - Puma Biotechnology Reports Second Quarter 2012 Financial Results
Read
August 7, 2012 - Puma Biotechnology to Present at Wedbush PacGrow Life Sciences Conference
Read
June 2, 2012 - Puma Biotechnology Presents Positive PB272 Clinical Data at ASCO 2012 Annual Meeting
Phase I Results Demonstrate Safety and Efficacy of PB272 in Combination with Paclitaxel and Trastuzumab in Women with Metastatic HER-2 Positive Breast Cancer
Read
May 30, 2012 - Puma Biotechnology to Present at Jefferies Healthcare Conference
Read
May 17, 2012 - Puma Biotechnology to Present Clinical Data on PB272 at ASCO 2012 Annual Meeting
Read
May 9, 2012 - Puma - Merrill Lynch Health Care Conference
Read
April 16, 2012 - Puma Biotechnology Cleared for Quotation on OTCBB and OTC LINK
Read
February 28, 2012 - Puma Biotechnology to Present at Cowen Health Care Conference
Read
February 9, 2012 - Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference
Read
January 4, 2012 - Puma Biotechnology to Present at 30th Annual J.P. Morgan Healthcare Conference
Read
2011 News Releases
December 9, 2011 - Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Read
November 23, 2011 - Puma Biotechnology Announces Completion of Private Placement Raises second tranche of capital bringing total offering proceeds to $60 Million
Read
October 5, 2011 - Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational PanHER Inhibitor; Closes $55 Million Private Placement and Completes Merger
Read
|
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
|
